Quoin Pharmaceuticals Ltd's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Quoin Pharmaceuticals Ltd (QNRX) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Quoin Pharmaceuticals Ltd vs Its Competitors
- Scale: Quoin Pharmaceuticals Ltd ranks #388 of 544 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.0% of industry market cap.
- Peer differentiation: Revenue per employee of $-0.01M compares with $0.45M for the peer group (0.0x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
API endpoints for this dataset
Quoin Pharmaceuticals Ltd's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Quoin Pharmaceuticals Ltd | - | No | No | No |
| Competitors combined (17) | ||||
| High-Confidence Competitors (7) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
QNRX Stock Performance relative to its Competitors
QNRX Stock Performance relative to High-Confidence Competitors
QNRX Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Longeveron Inc | 282.9% | Outperformed |
| 2 | Ovid Therapeutics Inc | 282.9% | Outperformed |
| 3 | Praxis Precision Medicines Inc | 282.9% | Outperformed |
| 4 | Capricor Therapeutics inc | 282.9% | Outperformed |
| 5 | Moleculin Biotech Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Quoin Pharmaceuticals Ltd's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Quoin Pharmaceuticals Ltd's Comment on Competition and Industry Peers
Publicly Traded Peers of Quoin Pharmaceuticals Ltd
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Quoin Pharmaceuticals Ltd |
- | -0.08 |
 Praxis Precision Medicines Inc |
10,085.57 | 8.55 |
 Ardelyx inc |
782.52 | 468.22 |
 Capricor Therapeutics inc |
652.20 | 22.27 |
 Longeveron Inc |
103.55 | 1.19 |
 Fibrobiologics Inc |
6.25 | - |
| SUBTOTAL | 11,656.79 | 553.61 |
Sign in to see all competitors of Quoin Pharmaceuticals Ltd .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Quoin Pharmaceuticals Ltd versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Quoin Pharmaceuticals Ltd's Competitors Named by the Company
Competitive relationships identified from Quoin Pharmaceuticals Ltd reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Bellicum Pharmaceuticals Inc. | Company report | 85% |
| Kiadis Pharma N.V. | Company report | 85% |
| MolMed S.p.A. | Company report | 85% |
| Fortress Biotech Inc. | Company report | 85% |
| Mesoblast Ltd. | Company report | 85% |
| Erytech Pharma SA | Company report | 85% |
| Medeor Therapeutics | Company report | 85% |
| Pluristem Therapeutics Inc. | Company report | 85% |
| Athersys, Inc. | Company report | 85% |
| Gamida Cell Ltd. | Company report | 85% |
| Miltenyi | Company report | 85% |
| Fate Therapeutics Inc. | Company report | 85% |
| MEDIPOST Co., Ltd. | Company report | 85% |
| Talaris Therapeutics | Company report | 85% |
Company report basis, confidence, active dates and source counts for Quoin Pharmaceuticals Ltd's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Quoin Pharmaceuticals Ltd's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Ardelyx inc | Reportable 100.00 % |
| Longeveron Inc | Reportable Segment Aggregation Before Other Operating Segment 100.00 % |
| Lunai Bioworks Inc | Bio Symetrics 100.00 % |
| International Stem Cell Corporation | Biomedical Market 93.74 % |
| Ovid Therapeutics Inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Quoin Pharmaceuticals Ltd's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd | - | -14,157 | -3,264,651 |
| Praxis Precision Medicines Inc | 10,086 | 50,911 | -2,018,607 |
| Ardelyx inc | 783 | 957,505 | -113,436 |
| Capricor Therapeutics inc | 652 | 96,409 | -568,567 |
| Longeveron Inc | 104 | 31,237 | -617,737 |
| Fibrobiologics Inc | 6 | - | -1,209,267 |
| PEERS TOTAL | 11,657 | 447,252 | -381,872 |
Sign in to see all peers for Quoin Pharmaceuticals Ltd .
Quoin Pharmaceuticals Ltd's Position in Industry Market Structure
Market-capitalization share and concentration across all 491 companies in Quoin Pharmaceuticals Ltd's industry classification, broader than the peer set above. Market cap in millions of $.Quoin Pharmaceuticals Ltd ranks #388 of 491 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 987, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,284,631 | 24.00 % |
| 2 | Johnson and Johnson | 684,228 | 12.78 % |
| 3 | Abbvie Inc | 522,410 | 9.76 % |
| 4 | Merck and Co Inc | 363,559 | 6.79 % |
| 5 | Novartis Ag | 1,234 | 5.2% |
| 6 | Abbott Laboratories | 1,234 | 5.2% |
| 7 | Novo Nordisk A | 1,234 | 5.2% |
| 8 | Pfizer Inc | 1,234 | 5.2% |
| 9 | Astrazeneca Plc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 388 | Quoin Pharmaceuticals Ltd | 11 | 0.00 % |
Market cap and industry share for the rest of Quoin Pharmaceuticals Ltd's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-11.
Quoin Pharmaceuticals Ltd's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 383 | Tvardi Therapeutics Inc | 13 | -63.96 % |
| 384 | Biofrontera Inc | 12 | -10.10 % |
| 385 | Lisata Therapeutics Inc | 11 | -47.62 % |
| 386 | Kairos Pharma Ltd | 11 | -46.77 % |
| 387 | Bullfrog Ai Holdings Inc | 1,234 | 12.3% |
| 388 | Quoin Pharmaceuticals Ltd | 11 | - |
| 389 | Bolt Biotherapeutics Inc | 1,234 | 12.3% |
| 390 | Dar Bioscience Inc | 1,234 | 12.3% |
| 391 | Geovax Labs Inc | 1,234 | 12.3% |
| 392 | Phio Pharmaceuticals Corp | 1,234 | 12.3% |
| 393 | Biovie Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Quoin Pharmaceuticals Ltd's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-11. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Quoin Pharmaceuticals Ltd's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (447 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 0.43 % | 38.09 % (avg) | -37.7 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | - | -6.73 % (avg) | - |
| Capital Intensity (Capex / Revenue) | 0.00 % | 7.49 % (avg) | -7.5 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Quoin Pharmaceuticals Ltd's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - | - | - | -91.57 % |
| Operating Margin | - | - | - | - | - | - | - | - |
| Return on Invested Capital | 113.36 % | 68.67 % | 44.33 % | - | - | -47.64 % | -52.47 % | -134.22 % |
| P/E | 2,224,589.6x | 2,363,692.8x | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Quoin Pharmaceuticals Ltd's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Quoin Pharmaceuticals Ltd falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.2% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Quoin Pharmaceuticals Ltd's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 987 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 0.00 % vs industry average 7.49 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Quoin Pharmaceuticals Ltd's dedicated Suppliers and Customers pages, not here.
Quoin Pharmaceuticals Ltd's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Quoin Pharmaceuticals Ltd falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Quoin Pharmaceuticals Ltd's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 165.9 points below the industry aggregate.
- Low relative market share vs the industry leader (0.00x).
Opportunities
- A meaningful share of competitors (52.90 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Quoin Pharmaceuticals Ltd's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd | 0.94 | 3.65 | - |
| Praxis Precision Medicines Inc | 11.53 | 11.58 | - |
| Ardelyx inc | 0.53 | 3.60 | 1.45 |
| Capricor Therapeutics inc | 3.58 | 7.13 | - |
| Longeveron Inc | 2.25 | 2.49 | - |
| Fibrobiologics Inc | 1.18 | 1.62 | 0.37 |
Sign in to see all peers for Quoin Pharmaceuticals Ltd .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Quoin Pharmaceuticals Ltd's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd | Q3 2026 | - | - |
| Praxis Precision Medicines Inc | Q2 2026 | - | - |
| Ardelyx inc | Q3 2026 | +15.7 % | - |
| Capricor Therapeutics inc | Q3 2026 | - | - |
| Longeveron Inc | Q2 2026 | -9.2 % | - |
| Fibrobiologics Inc | Q2 2026 | - | - |
| PEERS TOTAL | +13.7 % | - |
Sign in to see all peers for Quoin Pharmaceuticals Ltd .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Quoin Pharmaceuticals Ltd's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd | Q3 2026 | - | - |
| Praxis Precision Medicines Inc | Q2 2026 | - | +1,717.9 % |
| Ardelyx inc | Q3 2026 | +14.0 % | - |
| Capricor Therapeutics inc | Q3 2026 | - | +1,941.7 % |
| Longeveron Inc | Q2 2026 | -38.2 % | -60.8 % |
| Fibrobiologics Inc | Q2 2026 | - | - |
Sign in to see all peers for Quoin Pharmaceuticals Ltd .
Quoin Pharmaceuticals Ltd's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd | - | - | - |
| Praxis Precision Medicines Inc | - | - | - |
| Ardelyx inc | - | - | - |
| Capricor Therapeutics inc | - | - | - |
| Longeveron Inc | - | - | - |
| Fibrobiologics Inc | - | - | - |
Sign in to see all peers for Quoin Pharmaceuticals Ltd .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Quoin Pharmaceuticals Ltd's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Quoin Pharmaceuticals Ltd | - | - |
| Praxis Precision Medicines Inc | - | 1,179.19 |
| Ardelyx inc | - | 1.67 |
| Capricor Therapeutics inc | - | 29.29 |
| Longeveron Inc | - | 87.23 |
| Fibrobiologics Inc | - | - |
| PEERS AVERAGE | - | 21.06 |
Sign in to see all peers for Quoin Pharmaceuticals Ltd .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.